We, and others, have identified both specific and shared downstream targets of ERG and ETV1 in prostate carcinomas, supporting the existence of targetable molecular pathways that may overcome the challenges in direct targeting ETS transcription factors as a therapeutic approach [12, 13]. This evidence concerns the gene ERG and prostate carcinoma.